$ACB

Canadian analysts show selective optimism, favoring gold miners and energy sectors, while retail and transportation see cautious outlooks. Key updates: Allied Gold (AAUC:CA) maintained Outperform at C$39.00, Aritzia (ATZ:CA) rated Buy at C$180.00, Athabasca Oil (ATH:CA) downgraded to Sell at C$12.00, and Cenovus Energy (CVE:CA) sees mixed target revisions.

Aurora Cannabis (ACB) advises shareholders to take no action on Curaleaf's hostile takeover bid, which has yet to be formally revised. Curaleaf's initial offer of $5.00 per share (0.4013 shares + $1.00 cash) is under review by Aurora's special committee. Aurora expects Curaleaf to provide pro forma financials and extend the bid timeline. The board will issue a formal recommendation once the review is complete. Shareholders have until December 4, 2026, to consider their options.

SpaceX (SPCX) rose 8% after Morgan Stanley reiterated its $300 target. Nu Holdings (NU) gained 13% on Brazilian election results. Vaxcyte (PCVX) surged 57% on vaccine trial results. Schneider Electric to buy PTC (PTC) for $22.6B. Curaleaf (CURLF) raised Aurora (ACB) offer to $5/share. C.H. Robinson (CHRW) to acquire RXO (RXO) for $5.8B. Cenovus (CVE) to buy Athabasca (ATH) for C$5.7B. Gunnison Copper (GCU) pre-cleared for NYSE listing.

Curaleaf (CURLF) improved its bid to buy Aurora Cannabis (ACB), offering $5.00 per share. The deal aims to acquire all outstanding common shares of Aurora.

The DEA suspended hearings on marijuana rescheduling to include a Government Accountability Office report, impacting cannabis companies like Aurora Cannabis (ACB). ACB's P/S ratio is 1.14, below its historical median of 4.3x, reflecting market skepticism. The company's GF Score is 63/100, indicating moderate fundamental health. Two institutional investors have added to their positions, despite ongoing losses and regulatory uncertainty.

Curaleaf (CURA) has made a hostile takeover bid for Aurora Cannabis (ACB), offering US$4 per share, a 45% premium. Aurora's board rejected the bid, citing undervaluation and concerns over debt and voting power. Curaleaf seeks Aurora's international medical cannabis operations, aiming for US$1.5B revenue and US$350M EBITDA. The offer is open until December 1, with potential regulatory and shareholder decisions pending.

Curaleaf (CURLF) publicly offered $4 per share (cash/stock mix) to acquire Aurora Cannabis (ACB) in August 2026, citing lack of response. Aurora rejected, calling the offer undervalued and highlighting Curaleaf's $1B debt. Curaleaf sought to block Aurora's ATM stock sales plan, escalating tensions. Aurora's market cap is $266M; Curaleaf's is $2.9B.

Curaleaf rejected Aurora Cannabis's securities complaint, calling it a delay tactic. Aurora asked regulators to correct Curaleaf's bid circular on three points. Curaleaf responded, saying it would adjust the offer's expiration time and provide pro forma statements if due diligence is allowed. Aurora maintains the issues are about shareholder protection. The dispute involves a hostile takeover bid by Curaleaf.

Aurora Cannabis (ACB) filed an application with the Alberta Securities Commission, alleging Curaleaf's (CURA) hostile bid circular has deficiencies, including missing pro-forma financials and insufficient time for shareholders to evaluate the offer. Aurora's board unanimously recommends shareholders reject the bid. The company seeks an order to correct these issues and extend the bid period.

Aurora Cannabis (ACB) rose 4.26% to $4.04, extending a 7-day winning streak. The company's P/S ratio is 1.08, below historical and industry medians, indicating market skepticism. GF Value™ suggests a 6.1% overvaluation. ACB's GF Score™ is 60, with strengths in valuation and momentum but weaknesses in profitability and growth. Institutional gurus have added shares, while insiders show no recent activity. The company's market cap is $254 million.